Le Lézard
Classified in: Health
Subjects: NPT, PER

Balas Begins Role as President and CEO of ALS Association


WASHINGTON, Dec. 7, 2017 /PRNewswire-USNewswire/ -- The ALS Association today announced that Calaneet Balas has begun her role as President and CEO. Her appointment marks the culmination of an orderly transition that was announced earlier this year. Balas previously served as the Association's Executive Vice President for Strategy.

ALS Logo (PRNewsfoto/The ALS Association)

"Calaneet is the perfect person to lead The ALS Association forward in our efforts to find treatments and a cure for ALS, while empowering people with the disease," said Stephen Winthrop, Board Chair of The ALS Association. "Calaneet brought considerable experience leading organizations with her to The ALS Association and she has since been critical to integrating our core mission areas ? research, care services, and advocacy."

Balas was hired in June 2016 to oversee the integration of the organization's research, care services, and advocacy missions. She had previously served as CEO of the Ovarian Cancer National Alliance. In this role, she successfully collaborated with a partner organization to create the largest global organization dedicated to ovarian cancer research, advocacy, and patients. Her extensive experience also includes roles at the Arthritis Foundation, where she was Chief Strategy Officer of the Mid-Atlantic Region and President and CEO of the foundation's Metro DC Chapter.

"It's a tremendous honor to take on this new role leading our dedicated staff, chapters, and volunteers, who are working tirelessly on behalf of people living with ALS," Balas said. "I'm grateful for their support and I look forward to continuing to work with them to serve and empower people with ALS."

About ALS
ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. Eventually, people with ALS lose the ability to initiate and control muscle movement, which often leads to total paralysis and death within two to five years of diagnosis. For unknown reasons, veterans are twice as likely to develop ALS as the general population.

About The ALS Association
The ALS Association is the only national non-profit organization fighting Lou Gehrig's Disease on every front. By leading the way in global research, providing assistance for people with ALS through a nationwide network of chapters, coordinating multidisciplinary care through certified clinical care centers, and fostering government partnerships, The ALS Association builds hope and enhances quality of life while aggressively searching for new treatments and a cure. For more information about The ALS Association, visit our website at www.alsa.org.

 

SOURCE The ALS Association


These press releases may also interest you

at 16:20
The Board of Directors of Revvity , today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 9, 2024 to all shareholders of record at the close of business on July 19, 2024. About Revvity ...

at 16:20
Edwards Lifesciences today reported financial results for the quarter ended March 31, 2024. Highlights and Outlook Q1 sales grew 10% on a reported and constant currency1 basis to $1.6 billion Q1 TAVR sales grew 6%; constant currency sales...

at 16:16
A functional assessment of Bacillus subtilis PLSSC (SEBtilistm) demonstrated its antimicrobial activity and capability to offer health benefits through industrial processing and the digestion process, showing its value-add in functional foods,...

at 16:15
Cronos Group Inc. ("Cronos" or the "Company") will hold its 2024 first quarter earnings conference call on Thursday, May 9, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for...

at 16:05
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today...

at 16:05
Stevanato Group S.p.A. , a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first...



News published on and distributed by: